Gyre Therapeutics(GYRE) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million ...